PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
International Neurourology Journal10.5213/inj.2142382.1912022262119-128Efficacy and Safety of DA-8010, a Novel M3 Antagonist, in Patients With Overactive Bladder: A Randomized, Double-Blind Phase 2 StudyHee Seo Son, Cheol Young Oh, Myung-Soo Choo, Hyeong Gon Kim, Joon Chul Kim, Kyu-Sung Lee, Dong Gil Shin, Sung Yong Cho, Seong Jin Jeong, Ju Tae Seo, Hana Yoon, Hong Sang Moon, Jang Hwan Kimhttp://einj.org/upload/pdf/inj-2142382-191.pdf, http://einj.org/journal/view.php?doi=10.5213/inj.2142382.191, http://einj.org/upload/pdf/inj-2142382-191.pdf
Yearbook of Urology10.1016/j.yuro.2014.03.0032014201468-69A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicentre Study to Assess the Efficacy and Safety of the β3 Adrenoceptor Agonist, Mirabegron, in Patients With Symptoms of Overactive BladderE.S. Rovnerhttps://api.elsevier.com/content/article/PII:S0084407114000384?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0084407114000384?httpAccept=text/plain
International Journal of Urology10.1111/j.1442-2042.2008.02104.x2008159809-815A randomized, double-blind, placebo-controlled phase II dose-finding study of the novel anti-muscarinic agent imidafenacin in Japanese patients with overactive bladderYukio Homma, Takuhiro Yamaguchi, Osamu Yamaguchihttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1442-2042.2008.02104.x, http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1442-2042.2008.02104.x/fullpdf
Yearbook of Urology10.1016/s0084-4071(10)79446-x2010201036-37Efficacy and Safety of Oxybutynin Chloride Topical Gel for Overactive Bladder: A Randomized, Double-Blind, Placebo Controlled Multicenter StudyE.S. Rovnerhttps://api.elsevier.com/content/article/PII:S008440711079446X?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S008440711079446X?httpAccept=text/plain
European Urology10.1016/j.eururo.2015.02.01720156761189-1190Re: Combination Treatment with Mirabegron and Solifenacin in Patients with Overactive Bladder: Efficacy and Safety Results from a Randomised, Double-blind, Dose-ranging, Phase 2 Study (Symphony)Francisco Cruzhttps://api.elsevier.com/content/article/PII:S0302283815001712?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0302283815001712?httpAccept=text/plain
Journal of Urology10.1016/j.juro.2013.11.019201419141014-1021A Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Oxybutynin Vaginal Ring for Alleviation of Overactive Bladder Symptoms in WomenMarc Gittelman, Herman Weiss, Larry Seidmanhttps://api.elsevier.com/content/article/PII:S0022534713059132?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0022534713059132?httpAccept=text/plain, http://www.jurology.com/doi/pdf/10.1016/j.juro.2013.11.019
Current Therapeutic Research10.1016/j.curtheres.2009.11.0012009706405-420Efficacy and safety of solifenacin succinate 10 mg once Daily: A multicenter, phase III, randomized, double-blind, placebo-controlled, parallel-group trial in patients with overactive bladderFranklin Chu, Neila Smith, Takeshi Uchidahttps://api.elsevier.com/content/article/PII:S0011393X09001027?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0011393X09001027?httpAccept=text/plain
Clinical Medicine Insights: Urology10.4137/cmu.s496020104CMU.S4960Efficacy and Safety of 10 mg Solifenacin Succinate in Patients with Overactive Bladder Syndrome: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Pivotal TrialFred E Govier, Neila Smith, Takeshi Uchidahttp://journals.sagepub.com/doi/pdf/10.4137/CMU.S4960, http://journals.sagepub.com/doi/full-xml/10.4137/CMU.S4960, http://journals.sagepub.com/doi/pdf/10.4137/CMU.S4960
Yearbook of Urology10.1016/j.yuro.2011.05.0452011201125-26Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging TrialE.S. Rovnerhttps://api.elsevier.com/content/article/PII:S0084407111000637?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0084407111000637?httpAccept=text/plain
International Journal of Urology10.1111/iju.138922018263375-376Editorial Comment to Efficacy of novel β 3 ‐adrenoreceptor agonist vibegron on nocturia in patients with overactive bladder: A post‐hoc analysis of a randomized, double‐blind, placebo‐controlled phase 3 studyTakeya Kittahttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fiju.13892, https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.13892, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/iju.13892, https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.13892